| Amount | 10 mg, 20 mg, 30 mg |
|---|
HK-RT
Original price was: $49.99.$28.99Current price is: $28.99.
HK-RT is a catalog code for a triple-agonist incretin analog, available in 10 mg and 30 mg vials for laboratory research. Review the corresponding lot documentation before use. Not for human or veterinary use.
Coming soon. This compound is listed while photography and lot documentation are prepared. It cannot be purchased yet.
BEFORE YOU ORDER
Review the documentation.Check the current report status and match documentation to your vial’s lot.
Open documentation hub →RESEARCH COMPOUND
What is HK-RT?
HK-RT is Heavy Kingdom’s catalog code for a synthetic triple-agonist incretin analog (LY3437943). In laboratory research it is used to examine simultaneous activity at GLP-1, GIP, and glucagon receptors.
This listing is for laboratory research only. It is not a medicine, not for human or veterinary use, and this page does not provide dosing or administration guidance.
Mechanism of action
HK-RT is studied for concurrent engagement of three receptor targets used in metabolic signaling research:
- GLP-1R — glucagon-like peptide-1 receptor
- GIPR — glucose-dependent insulinotropic polypeptide receptor
- GCGR — glucagon receptor
The combined triple-agonist profile is of interest in research because it is distinct from single- or dual-receptor analogs. Heavy Kingdom does not claim clinical outcomes for this product.
Laboratory specifications
| Catalog name | HK-RT |
|---|---|
| Compound identity | LY3437943 |
| Type | Triple-agonist incretin analog (GLP-1 / GIP / glucagon) |
| CAS | 2381089-83-2 |
| Molecular formula | C256H392N64O79 |
| Molecular weight | ~4731 Da |
| Appearance | White to off-white lyophilized powder |
| Available amounts | 10 mg and 30 mg vials |
| Intended use | Laboratory research only |
| Storage | Keep frozen, protected from light and moisture, according to your laboratory’s peptide-handling SOP |
Published literature
Peer-reviewed papers below are listed so researchers can locate background reading on this analog class. They are not product claims and do not describe Heavy Kingdom lots.
- Jastreboff et al., The New England Journal of Medicine (2023). Triple-hormone-receptor agonist — Phase 2 trial. PMID 37366315.
- Rosenstock et al., The Lancet (2023). GIP, GLP-1, and glucagon receptor agonist — Phase 2 trial. PMID 37385280.
For laboratory and research use only. Not for human or veterinary consumption. Match any analytical report to the lot printed on your vial before use.
Laboratory handling
| Form | Lyophilized powder in a sealed research vial |
|---|---|
| Lyophilized storage | Keep sealed, desiccated, and protected from light. Typical research storage is −4°F (−20°C) (or −112°F (−80°C) for longer holds). Unopened vials may be held at 36°F–46°F (2°C–8°C) for short periods. Follow your laboratory SOP. |
| After reconstitution | Typical research handling is refrigeration at 36°F–46°F (2°C–8°C), use within about 30 days, and avoiding repeated freeze–thaw cycles. Warm sealed vials to room temperature before opening. |
| Documentation | Match any analytical report to the lot printed on the vial. Product photos are not a substitute for a lot-specific report. |
| Intended use | Laboratory research only. Not for human or veterinary use, consumption, or diagnostic or therapeutic procedures. |

